Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.50 |
| ▸ | MAOA | P21397 | 8/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | SDHA | P31040 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CALML3 | P27482 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7081362 | 1.00 | MAOB (0.50) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7077059 | 0.93 | F10 (0.48) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7084658 | 0.93 | F10 (0.48) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7084662 | 0.93 | F10 (0.48) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7077056 | 0.93 | F10 (0.48) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7082646 | 0.92 | MAOB (0.44) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7082649 | 0.92 | MAOB (0.44) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7078760 | 0.91 | MAOB (0.45) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7078757 | 0.91 | MAOB (0.45) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL7081547 | 0.90 | F10 (0.58) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6617339-B1 | 5-Isoxazolyloxymethyl-3-((dihydroxypropanoyl)-4-tetrahydropyri dyl-3,5- difluorophenyl)oxazolidinone, or the phosphated derivative or its disodium salt; antibiotic with useful activity against Grampositive pathogens | SYNGENTA LIMITED (GB) | 2003-09-09 | — | — | US | disclosed |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | MAOB 1178/4885MAOA 1654/4885PTGS1 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.